Fluxus

What Fluxus does

Fluxus is a privately held, development-stage medical device company founded in 2016 and headquartered in Sunnyvale, California, that develops biochip-based detection platforms for ultra-high sensitivity diagnostics and bioanalytical applications. The company's core technology is optofluidics — an integration of advanced photonics, MEMS, chip fabrication, engineering, assay development, and reagent manufacturing — designed to enable single-molecule counting and 'any analyte, any setting' biomolecular detection positioned as a gold standard in ultrasensitive testing.

The product portfolio comprises four integrated SKUs: the Optofluidic Diagnostics Platform (the core detection system), Analytical Instruments (electro-mechanical readers), and two consumable lines (Optofluidic Cartridges and functional Biochips). Operations include cleanroom and BSL2 laboratory work, cGMP-compliant process validation (IQ/OQ/PQ), and on-site cartridge and instrument assembly at the Sunnyvale facility. The company serves clinical researchers, healthcare providers, and industry partners across disease detection, diagnosis, monitoring, and treatment use cases, with an emphasis on companion diagnostics, biomarker discovery, and personalized medicine.

Fluxus has been a wholly-owned subsidiary of Fujirebio Holdings, Inc. since its 2022 acquisition, combining Silicon Valley startup R&D with the multinational IVD parent's global reach. Revenue is expected to come from instrument/hardware sales paired with a recurring razor-and-blade consumables stream (cartridges and reagents), distributed through direct enterprise engagement with healthcare providers, research institutions, and industry partners; however, the company remains pre-commercial with no disclosed revenue and continues to invest in product development, manufacturing scale-up, and regulatory preparation.

Name

Fluxus

Legal name

Fluxus, Inc.

Website

https://fluxus.bio

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Fluxus is a Sunnyvale-based, development-stage medical device subsidiary of Fujirebio Holdings that builds optofluidic biochip detection platforms for ultra-high sensitivity diagnostics. It serves clinical researchers, healthcare providers, and industry partners targeting single-molecule counting and ultrasensitive biomolecular testing.

Ownership category

akta.pro rank

Product category

In vitro diagnostics instrumentation

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

Keywords

• Optofluidic diagnostics platforms
• Single-molecule detection
• Biochip-based diagnostics
• Ultra-sensitive IVD instruments
• Bioanalytical assay systems

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure

Revenue model

1. Biochip-based Diagnostic Platforms: Revenue expected from sale of biochip-based detection platforms and instruments for ultra-high sensitivity diagnostics. As a development-stage company, commercial launch is pending.
2. Consumables and Reagents: Sale of optofluidic cartridges and assay reagents as recurring consumables for the diagnostic platforms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Fluxus develops optofluidic biochip-based detection platforms for ultra-high sensitivity diagnostics and bioanalytical applications. The offering combines proprietary biochips, single-use optofluidic cartridges, electro-mechanical analytical instruments, and associated assays and reagents to enable single-molecule counting across research, clinical, and patient settings.

Product overview

Fluxus offers a unified portfolio of optofluidic-based products for ultrasensitive bioanalysis. The core offering is the Optofluidic Diagnostics Platform (biochip-based detection system) paired with compatible Analytical Instruments for readout. The product line includes Optofluidic Cartridges and Biochips as consumables designed for single-molecule counting and ultra-high sensitivity diagnostics and bioanalytical applications. Fluxus positions these products for clinical research, diagnostics, and bioanalytical applications with an emphasis on 'Any Analyte, Any Setting' versatility.

Differentiator

Problem solved

Functional benefit

Products and services

• Optofluidic Diagnostics Platform Biochip-based detection platform enabling single-molecule counting and ultrasensitive biomolecular testing for disease detection, diagnosis, monitoring, and treatment. Targeted at clinicians, researchers, and industry partners in diagnostics.
• Biochips Functional biochips developed for detection and analysis in biomolecular sensing applications, integrated with Fluxus's optofluidic diagnostic platforms.
• Optofluidic Cartridges Single-use optofluidic cartridges designed for ultra-high sensitivity diagnostics and bioanalytical applications, assembled on Fluxus's Sunnyvale production line.
• Analytical Instruments Electro-mechanical instruments designed to read and analyze biochip-based optofluidic diagnostic platforms, integrating assays, consumables, instruments, and software.

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Quanterix: Quanterix's Simoa (Single Molecule Array) platform is the most direct competitor to Fluxus's single-molecule counting optofluidic technology, both targeting ultra-sensitive protein biomarker detection for clinical research and diagnostics.
• Meso Scale Diagnostics: Meso Scale Diagnostics offers ultrasensitive electrochemiluminescence immunoassay platforms for biomarker detection, competing with Fluxus in the high-sensitivity immunoassay / biomarker research segment.
• Singulex: Singulex pioneered single-molecule counting immunoassay technology (Erenna), directly comparable to Fluxus's single-molecule detection approach for ultra-sensitive protein biomarker measurement.

Broad incumbents

• Abbott Diagnostics: Abbott's Alinity and ARCHITECT immunoassay platforms are broad incumbent IVD systems that compete with Fluxus in clinical diagnostics; while not focused on single-molecule sensitivity, they dominate routine immunoassay placements globally.
• Roche Diagnostics: Roche's cobas Elecsys immunoassay platform is a global IVD incumbent; Roche also competes in high-sensitivity cardiac and infectious disease biomarker testing where Fluxus's single-molecule sensitivity could differentiate.
• Siemens Healthineers: Siemens Healthineers' Atellica and ADVIA Centaur immunoassay systems are established IVD incumbents competing for the clinical lab and biomarker testing workflows Fluxus targets.
• Bio-Rad Laboratories: Bio-Rad's Bio-Plex multiplex immunoassay systems and digital droplet PCR platforms compete with Fluxus in research-grade high-sensitivity detection for biomarker discovery and clinical research.
• Bio-Techne: Bio-Techne's ProteinSimple Simple Western and Ella immunoassay platforms target sensitive protein detection in research and bioprocessing — an adjacent but comparable high-sensitivity detection offering to Fluxus's cartridge-based platform.

Emerging players

• Olink Holding: Olink's proximity extension assay (PEA) technology enables high-sensitivity multiplex proteomic biomarker detection; it overlaps with Fluxus's biomarker discovery and clinical research use cases as a complementary/competing approach.

Others

• Fujirebio Holdings: Fujirebio is Fluxus's parent company and a major IVD diagnostics player; it is the primary commercial channel and ecosystem partner for Fluxus's optofluidic platform into clinical IVD markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fluxus